Avecho Biotechnology (ASX:AVE) FCF Margin % : -10,296.30% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Avecho Biotechnology's Free Cash Flow for the six months ended in Dec. 2023 was A$-2.78 Mil. Avecho Biotechnology's Revenue for the six months ended in Dec. 2023 was A$0.03 Mil. Therefore, Avecho Biotechnology's FCF Margin % for the quarter that ended in Dec. 2023 was -10,296.30%.

As of today, Avecho Biotechnology's current FCF Yield % is -25.09%.

The historical rank and industry rank for Avecho Biotechnology's FCF Margin % or its related term are showing as below:

ASX:AVE' s FCF Margin % Range Over the Past 10 Years
Min: -672.3 Med: -386.36 Max: 27.8
Current: -672.3

During the past 13 years, the highest FCF Margin % of Avecho Biotechnology was 27.80%. The lowest was -672.30%. And the median was -386.36%.

ASX:AVE's FCF Margin % is ranked worse than
70.83% of 1042 companies
in the Biotechnology industry
Industry Median: -139.2 vs ASX:AVE: -672.30

Avecho Biotechnology FCF Margin % Historical Data

The historical data trend for Avecho Biotechnology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology FCF Margin % Chart

Avecho Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

27.80

-371.17

-415.87

-142.45

-670.89

Avecho Biotechnology Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-275.76	-12.66	-362.28	-89.69	-10,296.30

Competitive Comparison of Avecho Biotechnology's FCF Margin %

For the Biotechnology subindustry, Avecho Biotechnology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avecho Biotechnology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's FCF Margin % falls into.

Avecho Biotechnology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Avecho Biotechnology's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-3.18	/	0.474
	=	-670.89 %

Avecho Biotechnology's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.78	/	0.027
	=	-10,296.30 %

Avecho Biotechnology FCF Margin % Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avecho Biotechnology (ASX:AVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

OEZ:Germany

Address

Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.avecho.com.au

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology (ASX:AVE) Headlines

No Headlines